Objective: We evaluated the subclinical shedding of six different herpesviruses in antiretroviral drug-treated HIV-positive [HIV(þ)] MSM, and determined how this is associated with markers of inflammation and immune activation.
Introduction
Despite the increase in life expectancy of HIV-1-infected patients on effective antiretroviral therapy (ART), chronic HIV infection has been associated with increased risk for non-AIDS-associated chronic diseases such as cardiovascular disease, dementia, osteoporosis, and HIV-associated malignancies [1] [2] [3] [4] [5] . This increased risk has been linked to elevated levels of systemic inflammation [6] [7] [8] . It is hypothesized that elevated levels of T-cell immune activation in chronic, treated HIV could be because of: preferential depletion of CD4 þ T cells in the gut mucosa early in infection leading to the translocation of microbial products [9, 10] ; reactivation of other viruses such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV) [11] [12] [13] [14] [15] ; and T-cell dysregulation [16, 17] . Any one or a combination of these mechanisms could lead to the elevated levels of T-cell activation and increased systemic inflammation.
A significant proportion of humans, depending on geographic locale, age, socioeconomic status, person-toperson close contact, and HIV-1 infection, have latent and life-long herpesvirus infections. Herpesviruses infections are common in MSM, with CMVand EBV having a more than 90-95% seroprevalence in HIV-1-infected and seronegative MSM in the Multicenter AIDS Cohort Study (MACS) [18] . Indeed, CMV-specific memory T cells are found in large numbers in the blood of both HIVpositive [HIV(þ)] and HIV negative [HIV(À)] elderly individuals, presumably because of repeated T-cell expansion in response to persistent CMV reactivation and antigen turnover from latent reservoirs [19, 20] , resulting in an exhausted and senescent T-cell phenotype [21] .
In a study by Hunt et al. [22] , HIV-infected individuals with incomplete T-cell recovery on ART who received the CMV drug valganciclovir, had a significant decrease in CD8 þ T-cell activation compared with those who received placebo, suggesting that CMV reactivation in blood or other anatomic compartments could be driving T-cell activation. In addition, CMV replication in semen of virally suppressed HIV-infected individuals has been associated with seminal shedding of HIV as well as higher levels of proviral HIV DNA in blood [12, 23] . A similar association has been seen between higher levels of EBV DNA and HIV DNA in blood [24] , and concomitant seminal shedding of EBV and CMV with HIV-1 levels in blood and semen [25] . Apart from semen and blood, herpesviruses have also been detected in the oral cavity of treated HIV-infected children [26] . Furthermore, given the altered enteric virome in pathogenic simian immunodeficiency virus infection [27] and in AIDS [28] , persistent herpesvirus shedding could also be present in stool of treated individuals. As such, evaluation of these different compartments for herpesvirus shedding over time will be important in determining whether asymptomatic reactivation could propel chronic, persistent immune activation, and elevated levels of systemic inflammation. In this study, we therefore explored the presence of subclinical reactivation of six different herpesviruses in five body compartments among 15 treated HIV(þ) MSM compared with 12 age-matched, CMV antibody(þ), HIV(À) controls at four different timepoints over 24 weeks, and evaluated whether herpesvirus reactivation correlated with levels of immune activation and inflammation.
Methods
Participants and samples Participants for this study were recruited from the Pittsburgh clinical site in the MACS, an ongoing prospective cohort study of HIV infection, comprised of MSM from Pittsburgh, Pennsylvania, USA [29] . This study was approved by the University of Pittsburgh (IRB# PRO12030691). Written informed consent was obtained from all study participants.
We enrolled HIV-1-infected, CMV immunoglobulin G (IgG) antibody(þ) individuals who were virally suppressed on ART for at least 48 weeks and had CD4 þ T-cell counts at least 500 cells/ml [HIV(þ)]. We also enrolled agematched (AE 2 years) CMV IgG antibody(þ) HIV-1-seronegative controls [HIV(À)]. Participants receiving acyclovir, valacyclovir, famciclovir, ganciclovir, or valganciclovir were excluded, and use of these medications was asked at every study visit. Blood (plasma and whole blood), throat washings, semen, urine, and stool were obtained from each participant at four study visits (0, 4, 8, and 24 weeks) to evaluate levels of EBV, CMV, herpes simplex virus 1 and 2 (HSV1 and HSV2), and human herpesvirus 6 and 8 (HHV6 and HHV8) DNA. At the same timepoints, peripheral blood mononuclear cells (PBMC) and plasma were collected for immunologic assays.
Herpesvirus serology testing
To determine serostatus for each herpesvirus, a cryopreserved serum sample obtained from each participant from the MACS visit date prior to enrollment to this study was sent to a commercial clinical laboratory to determine the presence of IgG antibodies to CMV, EBV (viral capsid antigen and nuclear antigen), HSV1 and 2, HHV6, and HHV8 using ELISA.
Nucleic acid extraction and herpesvirus DNA quantitation Nucleic acid was extracted from each sample using the EasyMag (bioMérieux, Durham, North Carolina, UAS) automated extractor following manufacturer's protocol. Before extraction, each specimen was spiked with 11 000 copies of a DNA phocine herpesvirus 1 for quality control of the extraction and PCR amplification procedures.
The extracted DNA was quantitated for HSV-1, HSV-2, CMV, EBV, HHV-6, HHV-8, and phocine herpesvirus 1 by real-time Taqman quantitative PCR with respective primer pairs and probes (see supplemental methods for assay specifics, including the specific primers, probes, and limits of detection for each herpesvirus evaluated; http:// links.lww.com/QAD/B145) [30] [31] [32] [33] [34] [35] [36] . For each PCR run, negative control, serial dilutions of the plasmids containing virus-specific target sequences or quantitated viral DNA were included for generating a standard curve for virus quantitation. The plasmid containing EBV amplicon-target fragment was provided by Wadowsky et al., Children's Hospital of Pittsburgh [35] . Quantitated HSV-1 and HSV-2 DNA were purchased from Advanced Biotechnologies (Columbia, Maryland, USA). All realtime PCR assays were performed using the same format of 5 ml sample DNA or standard control and 15 ml of reaction mix containing 10 ml of Taqman 2X Gene Expression Master Mix (Applied Biosystems, Foster City, California, USA) and a final concentration of 1.2 mmol/l forward and reverse primers and 0.3 mmol/l probe. Cycle conditions were identical for all quantitated DNA realtime PCR assays: stage 1, 508C for 2 min: stage 2 (Taq inhibitor inactivation), 958C for 10 min, and PCR amplification (45 cycles), 958C for 15 s and 608C for 1 min. Levels are expressed as copies/ml of specimen.
Measurement of percentage T-cell activation
Cryopreserved PBMCs from three timepoints (weeks 4, 8, 24) were thawed and stained with the following mAbs: anti-CD3 allophycocyanin (APC)-H7, anti-CD4 phycoerythrin (PE), CF594, anti-CD8 Alexa Fluor 700, antihuman leukocyte antigen D-related (HLA-DR), PE, anti-CD38 APC, all BD Biosciences. Fixed samples were analyzed within 24 h of staining using a BD LSRFortessa (BD Biosciences) and FlowJo version 10.0.7 software (TreeStar, Ashland, Oregon, USA). Antimouse immunoglobulin compensation beads stained with each appropriate fluorophore in the immune activation panel were used as compensation controls. Fluorescence minus one controls were used to set the gates for CD4 þ and CD8 þ T cells and immune activation markers.
Measurement of soluble marker levels
Stored plasma samples from all four timepoints were thawed and analyzed in batch. Commercially available ELISA kits were used to determine the plasma concentrations of soluble CD14 (sCD14; R&D, Minneapolis, Minnesota, USA), sCD163 (R&D), interleukin 6 (IL-6;( R&D), interferon g-induced protein 10 (IP-10; R&D), and C-reactive protein (CRP; R&D) according to manufacturer's instructions. Duplicates of 20% of the samples were included in each ELISA plate. Results were analyzed using an ELX808 ELISA reader (Biotek, Winooski, Vermont, USA) using Gen5 software v2.06.
Statistical analysis
GraphPad Prism v.6.05 (GraphPad Software, La Jolla, California, USA) was used for data analysis. Viral load and soluble marker results are expressed as log-converted means unless otherwise specified. Data are presented as means with standard error of the mean unless otherwise specified. Kruskal-Wallis test with Dunn's multiple comparison test were used to compare levels and rates of herpesvirus shedding and shedding in the different body compartments. Mann-Whitney test was used for nonparametric comparison of mean herpesvirus shedding rates, DNA levels, and mean levels of immune parameters between the two study groups. Differences with P values less than 0.05 were considered significant. Correlations were calculated using Spearman correlations. Only correlations with r values more than 0.5 (or <À0.5) and two-tailed P values less than 0.05 were considered significant.
Results
Study population and herpesvirus serologies Table 1 shows the baseline demographics of the two study populations. The median age of study participants at enrollment was 43 years (range 26-50); the majority of participants were Caucasian. In the HIV(þ) group, participants had been infected with HIV for a median of 9 years and had been virally suppressed on ART for a median of 7 years. They had median CD4 þ T-cell count of 803 cells/ml (range 555-1355) with a median CD4 þ % of 36. Among the HIV(þ) participants with available nadir CD4 þ T-cell counts (11/15), the median was 359 cells/ml (range 195-773), and none of them were Herpesvirus shedding in treated HIV Agudelo-Hernandez et al. 2087 
8 (53) 3 (25) The diagnosed with any AIDS-defining opportunistic infections. None of the participants reported recent fever, rash, upper respiratory infection symptoms (e.g. sore throat, cough, nasal congestion) or oral or genital ulcers at any study visit. All participants from both groups were positive for IgG to CMV, EBV, and HHV6. Although the HIV(þ) group had higher percentage of participants who had IgG to HSV1, HSV2, and HHV8, these were not significantly different from the HIV(À) group (P ¼ 0.66, P ¼ 0.18, and P ¼ 0.15, respectively). Figure 1a shows the means of the total herpesvirus shedding rate for the two study groups for the entire study. The shedding rate was calculated as the number of samples with (þ)herpesvirus DNA over the total number of specimens tested throughout the four study visits [e.g. if a participant is IgG(þ) for all the herpesviruses, the total number of samples tested for all the six herpeviruses ¼ 120 (5 specimens Â 4 timepoints Â 6 herpesviruses)]. HIV(þ) participants had a trend for a higher shedding rate compared with the HIV(À) group (mean of 11.4 vs. (P ¼ 0.041), whereas there was a trend for higher mean CMV DNA levels (P ¼ 0.056). No differences between the two groups were observed the other herpesviruses. The rate of herpesvirus DNA shedding was highest in the throat washings compared with other body compartments in both HIV(þ) and HIV(À) participants (Fig. 1c) . There were no differences in shedding rates among the other sampled compartments. Similarly, there was no difference in the shedding rates for each body compartment between the two study groups.
Subclinical herpesvirus shedding
Next, we compared whether herpesvirus shedding rates were similar across all study visits. Among the HIV(þ) groups, the shedding rates between visits that are within 4 weeks of each other (i.e. week 0 to week 4 and week 4 to week 8; Fig. 1d ) were significantly correlated. However, for visits that are more than a month apart, no correlation was observed ( Supplemental Fig 2A, Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6 shedding As all participants were IgG(þ) for EBV, CMV, and HHV6, we evaluated differences in reactivation of these herpesviruses among the two study groups. Figure 2a compares the shedding rates for EBV, CMV, and HHV6 DNA between the two groups. The HIV(þ) group had a higher EBV DNA shedding rate (mean of 21.0 vs. 12.5%; P ¼ 0.032). EBV was detected in the throat washings of all HIV(þ) participants (albeit not at every timepoint), whereas it was detected in seven of 12 HIV(À) participants (Supplemental Fig 1, http: //links.lww.com/QAD/B139). Similarly, the HIV(þ) group had a higher CMV DNA shedding rate (mean of 10.7 vs. 4.2%; P ¼ 0.039). CMV was mostly detected in semen (6/15) followed by urine and throat washings (both 4/15), whereas HHV6 was mostly detected in throat washings (14/15). There was no difference in the HHV6 shedding rate between the two groups. Figure 2b compares the shedding rates of the three herpesviruses in the two study groups. Among HIV(þ) participants, EBV shedding rates are higher than CMV, but are not different from HHV6, whereas among the HIV(À) group, both EBV and HHV6 had significantly higher shedding rates than CMV.
Herpesvirus shedding in treated HIV
Subclinical herpesvirus reactivation, immune activation, and inflammation in HIV As it is hypothesized that herpesvirus reactivation contributes to the increased levels of inflammation among treated HIV(þ) individuals, we evaluated associations between subclinical herpesvirus DNA shedding and the levels of immune activation and inflammation in the HIV(þ) study group. Using plasma and PBMC obtained at each timepoint we determined the average levels of monocyte (sCD14) and macrophage (sCD163) activation, systemic inflammation (IL-6, CRP, and IP-10), and T-cell activation (CD4
for each participant and compared the values between the two groups (Fig. 3a) . The soluble biomarkers chosen have been shown in previous studies as persistently elevated despite HIV suppression [37] or have been associated with non-AIDS chronic diseases or mortality in HIV-infected individuals [7, 8, 38] . T-cell activation is also associated with HIV disease progression [39] as well as impaired vascular health among virally suppressed individuals [40] . Plasma levels of sCD14 remained elevated in the HIV(þ) group despite viral suppression and CD4 þ T-cell reconstitution. There was also a trend for higher plasma-IP-10 levels in the HIV(þ) group. No differences were observed in the levels of sCD163, IL-6, and CRP. The CD4 þ and CD8 þ T-cell activation levels for the three timepoints were also similar between the two groups. Of these different immunologic parameters, only IP-10 and sCD163 had significant associations with the herpesvirus shedding rates. The log-transformed mean plasma levels of induced protein 10 (r ¼ À0.77; P ¼ 0.0001) as well as sCD163 (r ¼ À0.52; P ¼ 0.049) inversely correlated with the mean herpesvirus shedding rate (Fig. 3b) . These correlations were not observed in the HIV(À) group.
Next, we evaluated whether CMV, EBV, or HHV6 shedding rates among HIV(þ) participants are associated with the different immunologic parameters. Figure 4a shows a trend toward a significant positive correlation between EBV DNA shedding rate and plasma levels of sCD14 (r ¼ 0.51; P ¼ 0.053; Fig. 4a ). In contrast, CMV shedding rates were not associated with any of the immune parameters. However, among HIV(þ) participants who had subclinical CMV reactivation, the logtransformed levels of CMV DNA that reactivated at a particular time point negatively correlated with the frequencies of both CD8 þ (r ¼ À0.55; P ¼ 0.031) and CD4 þ T-cell activation (r ¼ À0.59; P ¼ 0.018) at the corresponding timepoints (Fig. 4b) . Figure 4c shows that HHV6 DNA shedding rates negatively correlated with plasma levels of IL-6 (r ¼ À0.67; P ¼ 0.007), IP-10 (r ¼ À0.79; P ¼ 0.0008), and sCD163 (r ¼ À0.71; P ¼ 0.004). In addition, the log-transformed mean HHV6 DNA copies shed negatively correlated with plasma interleukin 6 levels (r ¼ À0.60; P ¼ 0.02). Shedding rates from these three herpesviruses did not correlate with the levels of T-cell activation. These significant correlations were not observed in the HIV(À) group.
Discussion
The primary aim of this study was to define the characteristics of subclinical herpesvirus reactivation among ART-suppressed HIV(þ) men with CD4 þ Tcell reconstitution throughout a 6-month period, and evaluate whether these characteristics correlate with levels of inflammation and immune activation. Our study confirms previous findings of asymptomatic herpesvirus replication in HIV-infected individuals who are suppressed on ART [24, 41, 42] . Although there was only a modest trend for higher mean shedding rates among HIV(þ) participants compared to age-matched HIV(À) MSM, there are some significant findings among the HIV(þ) group that will have important implications in further studies on HIV-herpesvirus coinfection. First, shedding rates at each of the four timepoints did not necessarily correlate with each other. Only timepoints that were within 4 weeks of each other showed significant positive correlations. These results highlight the importance of obtaining samples at multiple timepoints as herpesvirus DNA measured at a single timepoint may not represent the broader viral DNA shedding burden that occurs among ART-treated HIV(þ) individuals.
Second, we showed that treated HIV(þ) MSM not only have CMV shedding rates but also have higher EBV shedding rates and shed significantly higher EBV DNA levels compared with HIV(À) MSM. These results stress the importance of including EBV in studies looking into the role of herpesviruses in chronic HIV-associated inflammation, to have a better picture of how coinfection can affect HIV immunopathogenesis.
Third, we observed frequent asymptomatic HHV6 DNA shedding in our population of treated HIV(þ) participants. HHV6 has been previously hypothesized to play a role in HIV disease progression among untreated individuals [43] . Although HHV6 shedding is common among immunocompetent individuals [44] , one previous study showed low levels of shedding among HIV(þ) individuals [45] . Conversely, our findings show HHV6 DNA shedding was common among HIV(þ) individuals, as DNA was detected in the throat washings of 14 of 15 HIV(þ) participants, with shedding rates similar to the HIV(À) group. We believe these findings have not been previously shown among ART-treated HIV(þ) individuals and could have important implications concerning persistent inflammation in treated HIV infection.
Fourth, comparison of herpesvirus DNA shedding within different body compartments showed that most episodes of shedding, specifically EBV and HHV6, were detected in throat washings rather than the other body compartments. Therefore, HIV-herpesvirus coinfection studies not evaluating virus reactivation in the oral compartment are likely understating the rates of herpesvirus DNA shedding. In addition, episodes of CMV shedding among HIV(þ) participants were higher in semen compared with blood. Consideration of where herpesviruses are most likely to reactivate can help in better designing studies that evaluate the relationship between herpesvirus coinfection and HIV persistence and levels of immune activation.
Last, we found significant correlations between several immune parameters of inflammation and immune activation and the frequency as well as the level of herpesvirus DNA shedding. When taken as a group, we observed negative correlations between herpesvirus shedding rates and some immunologic measures, that is, herpesvirus DNA loads were lower in participants with higher levels of inflammation. It is possible that lower levels of sCD163 and IP-10 could be allowing herpesviruses to reactivate rather than the reactivation driving the high levels of these soluble markers. Therefore, the presence residual immune dysfunction in treated HIV infection could be allowing increased reactivation of these herpesviruses. With CMV, although there were no correlations between the shedding rate and the immune parameters, the levels of CMV DNA among those with reactivation negatively correlated with the level T-cell activation at that timepoint. We hypothesize that in these participants, the higher levels of CMV DNA being shed resulted in increased expression of checkpoint inhibitors [46] such as the programmed death receptor 1, thereby leading to an exhausted T-cell phenotype and less immune activation. In contrast, we observed a modest trend for a positive correlation between EBV shedding rate and levels of plasma sCD14. EBV infection has been shown to play a role in inflammasome activation in monocytes [47] , so it is possible that higher rates of EBV shedding can lead to more activated monocytes. Indeed, our results showed the HIV(þ) group had higher levels of sCD14 as well as higher rates of EBV shedding. Further studies should determine the specific mechanisms by which EBV reactivation could contribute to higher levels of monocyte activation in treated HIV(þ) individuals, and subsequently higher systemic inflammation. We also report, for the first time, strong negative correlations between HHV6 DNA shedding rates and levels of interleukin 6, sCD163, and IP-10. This may be explained by the ability of HHV6 to modulate the immune system, as HHV6 has been shown impair the phenotype and function of antigen presenting cells, down modulate the CD3 þ /T-cell receptor complex, and expand regulatory T cells [48, 49] . As such, HHV6 DNA shedding can result in a more anti-inflammatory environment. Interestingly, these correlations were not observed among the agematched EBV/CMV/HHV6(þ) HIV(À) participants, pointing to the possibility of HIV-specific interactions with these herpesviruses affecting different immunologic parameters. It will, therefore, be important to determine the pathways by which HIV immune pathogenesis affects herpesvirus reactivation and vice versa so as to develop intervention strategies to lower levels in inflammation in treated HIV infection.
There are several limitations to our study. First is the small number of participants enrolled in each group. Also, as we are only assessing the MSM population, differences in the frequency and level of shedding as well as the correlations with the immune parameters are possible with HIV(þ) women and thus further studies are needed for comparison. Second, because of limited clinical information, it is possible that significant confounding variables such as other comorbidities and tobacco use, may have influenced the associations we describe. Third, we were not able to include two other herpesviruses, varicellazoster and human herpesvirus 7, both of which may have asymptomatic shedding and may contribute to the levels of systemic inflammation. Despite these limitations, our results underscore important factors that should be considered in future analyses of herpesvirus shedding to fully understand how coinfection with these viruses affect HIV pathogenesis. Additional studies should also be conducted to evaluate how the episodes of reactivation as well as the levels of herpesvirus DNA being shed correlate with markers of HIV persistence.
